<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704519</url>
  </required_header>
  <id_info>
    <org_study_id>18426</org_study_id>
    <secondary_id>2018-001599-39</secondary_id>
    <nct_id>NCT03704519</nct_id>
  </id_info>
  <brief_title>Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.</brief_title>
  <official_title>A Phase I, Randomized, Placebo-controlled, Open-label, Three Period Crossover Study to Investigate the Effect of Darolutamide and Enzalutamide on Cerebral Blood Flow in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will investigate the effects of a single dose of darolutamide and
      enzalutamide compared with placebo and compared to each other on human brain blood flow using
      arterial spin labeling magnetic resonance imaging (ASL-MRI), a non-invasive MRI technique.
      The change in cerebral blood flow is an indirect measure of brain penetration.

      The risk of drug-associated CNS-related adverse events is likely to be correlated with the
      concentration of the drug in the brain. In contrast to enzalutamide, preclinical studies of
      darolutamide indicate that its brain penetration is much lower.

      The aim of this study is to determine whether there is a difference between darolutamide and
      enzalutamide compared to placebo in cerebral blood flow and thus in brain penetration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to investigate drug-induced changes in grey matter cerebral blood
      flow during single-dose treatment with darolutamide or enzalutamide as compared to placebo
      using voxel-wise quantification of the grey matter for the entire brain.

      The secondary objective is to investigate drug-induced changes in regional cerebral blood
      flow in brain areas related to cognitive function after single-dose treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Actual">November 5, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in grey-matter cerebral blood flow of enzalutamide as compared to placebo</measure>
    <time_frame>At 4 hours after drug</time_frame>
    <description>Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of enzalutamide to placebo. Measured in grey matter voxels with arterial spin labeling magnetic resonance imaging (ASL-MRI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in grey-matter cerebral blood flow of darolutamide as compared to placebo</measure>
    <time_frame>At 4 hours after drug</time_frame>
    <description>Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of darolutamide to placebo. Measured in grey matter voxels with ASL-MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in grey-matter cerebral blood flow of enzalutamide as compared to darolutamide</measure>
    <time_frame>At 4 hours after drug</time_frame>
    <description>Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of enzalutamide to darolutamide. Measured in grey matter voxels with ASL-MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of enzalutamide as compared to placebo</measure>
    <time_frame>At 4 hours after drug</time_frame>
    <description>Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of darolutamide as compared to placebo</measure>
    <time_frame>At 4 hours after drug</time_frame>
    <description>Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of enzalutamide as compared to darolutamide</measure>
    <time_frame>At 4 hours after drug</time_frame>
    <description>Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Cerebrovascular Circulation</condition>
  <arm_group>
    <arm_group_label>Men_EPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men_DEP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men_PDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men_DPE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men_EDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men_PED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darolutamide (BAY1841788)</intervention_name>
    <description>300 mg tablet darolutamide, once orally</description>
    <arm_group_label>Men_DEP</arm_group_label>
    <arm_group_label>Men_DPE</arm_group_label>
    <arm_group_label>Men_EDP</arm_group_label>
    <arm_group_label>Men_EPD</arm_group_label>
    <arm_group_label>Men_PDE</arm_group_label>
    <arm_group_label>Men_PED</arm_group_label>
    <other_name>Darolutamide: ODM-201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>4 x 40 mg capsules, once orally</description>
    <arm_group_label>Men_DEP</arm_group_label>
    <arm_group_label>Men_DPE</arm_group_label>
    <arm_group_label>Men_EDP</arm_group_label>
    <arm_group_label>Men_EPD</arm_group_label>
    <arm_group_label>Men_PDE</arm_group_label>
    <arm_group_label>Men_PED</arm_group_label>
    <other_name>MDV3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 placebo tablets, once orally</description>
    <arm_group_label>Men_DEP</arm_group_label>
    <arm_group_label>Men_DPE</arm_group_label>
    <arm_group_label>Men_EDP</arm_group_label>
    <arm_group_label>Men_EPD</arm_group_label>
    <arm_group_label>Men_PDE</arm_group_label>
    <arm_group_label>Men_PED</arm_group_label>
    <other_name>Darolutamide-matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who are healthy as determined by medical history, physical examination,
             laboratory tests, and cardiac monitoring.

        Exclusion Criteria:

          -  Existing or recent relevant diseases of vital organs (eg, liver diseases, heart
             diseases, renal disease, lung disease), central nervous system or other organs (eg,
             Diabetes mellitus, myasthenia gravis).

          -  Known contraindication to magnetic resonance imaging.

          -  Any structural variants or pathological abnormalities on structural brain MRI during
             screening.

          -  Any history of seizures including a febrile seizure in childhood, loss of
             consciousness, transient ischemic attack, or any condition that may pre-dispose to
             seizure.

          -  Participant with any type of neurological problems or history of psychiatric disorder,
             especially mood disorders including medical history with suicidal ideation and/or
             suicide attempts, which may disable the participant to consent to the study.

          -  Participants who use prescription or oral over the counter medications which might
             influence the study objectives, dietary/nutritional supplements, (including vitamins,
             natural and herbal remedies, eg, St. John's wort) within 2 weeks prior to first study
             intervention administration or during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Neuroimaging Sciences, King's College</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Magnetic Resonance Imaging (MRI)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

